CHICAGO — The addition of panitumumab vs. bevacizumab to standard doublet chemotherapy significantly extended survival among patients with RAS wild-type and left-sided metastatic colorectal cancer, according to study results.The panitumumab (Vectibix, Amgen) regimen conferred median OS of more than 3 years —— the longest survival ever reported in a first-line, prospective phase